Who are we?
Medison is Israel’s leading pharmaceutical partner, uniquely qualified to provide the entire spectrum of integrated services for international companies in Israel’s healthcare market. Employing a comprehensive approach to marketing and service, Medison supplies and maintains long-standing relations with HMOs (Health Maintenance Organizations), local medical centers and physicians.
Backed by three generations of experience in the healthcare industry since 1937, Medison is uniquely qualified to provide the complete spectrum of integrated services for international companies looking to enter or expand their presence in the Israeli and Romanian healthcare markets.
SUCCESSFUL COMMERCIALIZATION
We work together with our partners to meet unmet medical
needs in a diverse range of therapeutic fields:
- Neuroscience
- Rare Diseases
- Oncology
- Hematology
- Cardiology
- Endocrinology
- Nephrology
- Palliative Care
more…
Drugs Disributed by Medison Pharma Ltd
siRNA. Vutrisiran 25 mg/0.5 ml. Pre-filled syr. with 0.5 ml sol. for inj.
Recommen. dose is 25 mg admin. by SC inject. once every 3 months. Vitamin A supplement. at approx., but not exceeding, 2,500 IU to 3 ,000 IU /d is advised.
Tmt. of hered. transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult with stage 1 or stage 2 polyneuropathy:
C/I:Hypersens.
Thrombin Inhibitor. Bivalirudin 250 mg/vial. VIALS (pwdr. for I.V. inject.): 1 x 10. I.V.
bolus: 1.0 mg/kg foll. by 4 hr. infus. at
rate of 2.5 mg/kg/hr. Aft. complete
initial 4 hr. infus., addition. I.V. infus.
may be initiat. at 0.2 mg/kg/hr. for up
to 20 hrs. if reqd. Use with aspirin (300
- 325 mg dly). Initiate just prior to
PTCA. May need to reduce dose and
anticoag. status monitored in pts. with
ren. impair.
Unstable ang. undergoing percutan.
translum. coron. angioplasty (PTCA). To
be used with aspirin. See lit. for safety
and effectiveness.
C/I: Known hypersens.
Immunomodulator. Interferon Beta-1a 30 mcg. PRE-FILL. SYR/PEN: 4.
SINGLE-USE VIAL: 4. 1 inject I.M. 1 x
wkly (self-inject. permitted).
Relapse form multiple sclerosis, slow
accumulation of physical disabil., decr.
freq. clinical exacerbations. Tmt. demyelinat. event with active inflamm.
process if severe enough to treat with I.V.
corticoster., if alt. diagn. excluded incl.
MRI abnorm. characters. of MS if at high
risk of develop. clin. defin. MS.
C/I: Hypersens. to natural or
recombinant interferon beta, human
albumin or any other component.
Fibrate. Bezafibrate 400 mg. S.R. TABS: 30. 1 tab dly in even.
Hyperlipidem. in types 11a, 11b, III, IV, V
where diet alone is insuffic.
C/I: Hypersens., pregn., lact., liver/
gallbladder dis., severe renal funct.
disords.
Kinase Inhibitor. encorafenib 75 mg. Hard Caps.180 x 75 mg
BRAF V600E or V600K Mutation-Positive Unresectable or Metast. Melanoma and for BRAF V600E Mutation-Positive Metast. Non-Small Cell Lung Cancer (NSCLC)- recommended dosage is 450 mg (six 75 mg caps.) orally 1 X d in combin. with binimetinib until dis. progress. or unacceptable tox.
BRAF V600E Mutation-Positive Metast. Colorectal Cancer (CRC)- recommended dosage is 300 mg (four 75 mg capsules) orally 1 X d in combin. with cetuximab until dis. progress. or unacceptable tox.
For adults with:
BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma or
BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)- as detected by an approved test, after prior ther.
BRAF V600E Mutation-Positive metastatic non-small cell lung cancer (NSCLC)- in combin. with binimetinib, when mutation detected by an approved test.
C/I: Hypersens.
